Please enable JavaScript.
Coggle requires JavaScript to display documents.
DRM 12/03/18 (FY sales -4.5m€ vs Plan (Opportunities (+2.2m gross, +1.5m…
DRM 12/03/18
FY sales -4.5m€ vs Plan
of which -2.2m discontinued products, -0.6m Polident no innovations
-
Opportunities (+2.2m gross, +1.5m prob)
Risks (-2.1m gross, -0.7m prob)
-
-
-
-
all gap coming from PH
PDX, Polident in OC; Cibalgina in Pain; Physiogel in Skin
Wellness Feb weekly S-O
-
Rinazina: 7 weeks in a row with MS gain, 4 weeks in a row with double digit growth
Nasal non medicated: issues on Respirabene (visibility, prioritization issues)
-
-
FY sales +2.5% vs PY reported, +4% L2L
-
-